Medical Instruments & Supplies · Healthcare
CFO
Equibles does not estimate personal net worth.
Get an email with a short summary when Orasure Technologies Inc publishes a filing, an earnings call transcript or a press release.
Get OSUR alertsKen McGrath is recorded as CFO at Orasure Technologies Inc (OSUR). Orasure Technologies Inc reported in an 8-K filed August 12, 2022 that Ken McGrath was appointed Chief Financial Officer, effective August 8, 2022. The proxy statement of Orasure Technologies Inc reports total compensation of $1,683,370 for Ken McGrath in fiscal 2024, including a base salary of $497,500. Disclosed compensation is on record for 5 fiscal years. Ken McGrath has spoken on 11 earnings calls across 1 company, most recently for Orasure Technologies Inc on November 9, 2026. Orasure Technologies Inc is classified in the Medical Instruments & Supplies industry within the Healthcare sector. Other leadership on record at Orasure Technologies Inc includes Carrie Eglinton Manner (CEO and Board Member), Nancy Gagliano (CEO and Board Member), Nancy J. Gagliano, M.D., M.B.A. (CEO) and 7 others.
“On August 8, 2022, the board of directors (the “Board”) of OraSure Technologies, Inc. (the “Company”) appointed Ken McGrath as the Company’s Chief Financial Officer, effective August 8, 2022 (the “Effective Date”).”
“Total revenue in the third quarter was $30.9 million, growing 14% year-over-year and approximately 1% on a sequential basis. Diagnostic products generated $16.8 million of revenue in Q3, representing 16% year-over-year growth.”
“Total revenue in the second quarter was $30.6 million and grew 9.7 percent on a sequential basis. Diagnostic products generated $19.4 million of revenue in Q2, with U.S. revenue higher than international revenue.”
“Total revenue in the first quarter was $27.9 million and grew 4% on a sequential basis. Diagnostic products generated $16.9 million of revenue in Q1, with a fairly even split between U.S. and international revenue.”
“Total revenue in the third quarter was $27.1 million. Core revenue, which excludes COVID-19 products and the molecular services and the risk assessment testing businesses that we exited, was $27 million.”
“I'm happy to discuss our first quarter results and financial outlook. Total revenue in Q1 was $29.9 million. Core revenue, which excludes COVID-19 products and the molecular services business that we exited was $29.5 million and decreased 2% compared to the prior year period.”
Medical Instruments & Supplies · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Orasure Technologies Inc (OSUR) | Chief Financial Officer | $497,500 | $1,683,370 |
| 2023 | Orasure Technologies Inc (OSUR) | Chief Financial Officer | $483,000 | $1,528,599 |
| 2022 | Orasure Technologies Inc (OSUR) | Chief Financial Officer | $173,558 | $838,808 |
| 2021 | Orasure Technologies Inc (OSUR) | Chief Financial Officer | — | — |
| 2020 | Orasure Technologies Inc (OSUR) | Chief Financial Officer | — | — |